| Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels AD Yalcin, B Celik, AN Yalcin Immunopharmacology and Immunotoxicology 38 (3), 253-256, 2016 | 60 | 2016 |
| IL‐8, IL‐10, TGF‐β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti‐IgE Treatment AD Yalcin, A Bisgin, RM Gorczynski Mediators of inflammation 2012 (1), 720976, 2012 | 56 | 2012 |
| A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels AD Yalcin Immunopharmacology and immunotoxicology 38 (2), 162-166, 2016 | 54 | 2016 |
| Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200 AD Yalcin, GE Genc, B Celik, S Gumuslu Clin Lab 60 (3), 523-4, 2014 | 47 | 2014 |
| Future perspective: biologic agents in patients with severe COVID-19 AD Yalcin, AN Yalcin Immunopharmacology and Immunotoxicology 43 (1), 1-7, 2021 | 42 | 2021 |
| An overview of the effects of anti-IgE therapies AD Yalcin Medical Science Monitor: International Medical Journal of Experimental and …, 2014 | 41 | 2014 |
| Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β … AD Yalcin, A Cilli, A Bisgin, LG Strauss, F Herth Expert opinion on biological therapy 13 (9), 1335-1341, 2013 | 39 | 2013 |
| Synthesis, characterization and, the heavy metal removal efficiency of MFe2O4 (M= Ni, Cu) nanoparticles N Sezgin, M Sahin, A Yalcin, Y Koseoglu Ekoloji 22 (89), 89-96, 2013 | 39 | 2013 |
| Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients A Bisgin, AD Yalcin, RM Gorczynski Diabetes Research and Clinical Practice 96 (3), e84-e86, 2012 | 39 | 2012 |
| Pollen aero allergens and the climate in Mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients AD Yalcin, S Basaran, A Bisgin, HH Polat, RM Gorczynski Medical Science Monitor: International Medical Journal of Experimental and …, 2013 | 38 | 2013 |
| Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer A Bisgin, A Kargi, AD Yalcin, C Aydin, D Ekinci, B Savas, S Sanlioglu BMC cancer 12, 1-5, 2012 | 37 | 2012 |
| Advances in anti‐IgE therapy AD Yalcin BioMed Research International 2015 (1), 317465, 2015 | 35 | 2015 |
| Perioperative antibiotic prophylaxis and cost in a Turkish University Hospital AN Yalcin, RH Erbay, S Serin, H Atalay, O Oner, AD Yalcin Infez Med 15 (2), 99-104, 2007 | 35 | 2007 |
| D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment AD Yalcin, B Celik, S Gumuslu Expert opinion on biological therapy 14 (3), 283-286, 2014 | 34 | 2014 |
| Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers HO Arık, AD Yalcin, S Gumuslu, GE Genç, A Turan, AD Sanlioglu Medical science monitor: international medical journal of experimental and …, 2013 | 34 | 2013 |
| Artemisinin attenuates doxorubicin induced cardiotoxicity and hepatotoxicity in rats I Aktaş, Ö Özmen, H Tutun, A Yalçın, A Türk Biotechnic & Histochemistry 95 (2), 121-128, 2020 | 33 | 2020 |
| Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up AD Yalcin, S Uçar, S Gumuslu, LG Strauss Immunopharmacology and immunotoxicology 35 (4), 524-527, 2013 | 33 | 2013 |
| Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma AD Yalcin, A Bisgin, R Cetinkaya, M Yildirim, RM Gorczynski Clin Lab 59 (1-2), 71-77, 2013 | 28 | 2013 |
| Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatment AD Yalcin, A Bisgin, A Kargi, RM Gorczynski Medical Science Monitor: International Medical Journal of Experimental and …, 2012 | 27 | 2012 |
| Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis AD Yalcin, S Gumuslu, GE Parlak, A Bisgin, M Yildiz, A Kargi, ... Immunopharmacology and immunotoxicology 34 (6), 1047-1053, 2012 | 26 | 2012 |
Gizem Esra GencRyerson University在 ryerson.ca 的电子邮件经过验证
